JP2022016416A5 - - Google Patents

Download PDF

Info

Publication number
JP2022016416A5
JP2022016416A5 JP2021114251A JP2021114251A JP2022016416A5 JP 2022016416 A5 JP2022016416 A5 JP 2022016416A5 JP 2021114251 A JP2021114251 A JP 2021114251A JP 2021114251 A JP2021114251 A JP 2021114251A JP 2022016416 A5 JP2022016416 A5 JP 2022016416A5
Authority
JP
Japan
Prior art keywords
severity
subject
expression level
mrna
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021114251A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022016416A (ja
JP7743217B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2022016416A publication Critical patent/JP2022016416A/ja
Publication of JP2022016416A5 publication Critical patent/JP2022016416A5/ja
Application granted granted Critical
Publication of JP7743217B2 publication Critical patent/JP7743217B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021114251A 2020-07-10 2021-07-09 アトピー性皮膚炎の重症度の検出方法 Active JP7743217B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020119040 2020-07-10
JP2020119040 2020-07-10

Publications (3)

Publication Number Publication Date
JP2022016416A JP2022016416A (ja) 2022-01-21
JP2022016416A5 true JP2022016416A5 (enExample) 2025-02-18
JP7743217B2 JP7743217B2 (ja) 2025-09-24

Family

ID=79552561

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021114251A Active JP7743217B2 (ja) 2020-07-10 2021-07-09 アトピー性皮膚炎の重症度の検出方法

Country Status (5)

Country Link
US (1) US20230265515A1 (enExample)
EP (1) EP4180536A4 (enExample)
JP (1) JP7743217B2 (enExample)
CN (1) CN115803450A (enExample)
WO (1) WO2022009988A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115279901A (zh) * 2020-03-11 2022-11-01 花王株式会社 来自皮肤表面脂质的rna的制备方法
WO2024232368A1 (ja) * 2023-05-08 2024-11-14 花王株式会社 アトピー性皮膚炎の重症度の検出方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005100602A (ja) * 2003-08-26 2005-04-14 Matsushita Electric Ind Co Ltd 記録媒体の原盤製造方法、スタンパ製造方法、記録媒体製造方法、記録媒体の原盤、記録媒体のスタンパ、記録媒体
JP6006906B1 (ja) * 2016-03-25 2016-10-12 花王株式会社 皮脂腺又は毛包選択的アンドロゲン受容体活性制御剤の評価又は選択方法
EP3719138B1 (en) 2016-07-08 2022-09-21 Kao Corporation Method for preparing nucleic acid sample
KR101818672B1 (ko) * 2017-02-17 2018-01-16 가천대학교 산학협력단 아토피 피부염 진단용 조성물 및 상기 조성물을 이용한 아토피 피부염의 진단 방법
US11911012B2 (en) * 2017-03-03 2024-02-27 Children's Hospital Medical Center Non-invasive methods for skin sample collection and analysis
EP3875585A4 (en) * 2018-11-01 2022-11-16 Kao Corporation Method for preparing nucleic acid derived from skin cell of subject
WO2021221138A1 (ja) * 2020-05-01 2021-11-04 花王株式会社 アトピー性皮膚炎の検出方法
CN115605608A (zh) * 2020-05-14 2023-01-13 花王株式会社（Jp） 帕金森氏病的检测方法

Similar Documents

Publication Publication Date Title
Chung et al. How variability in clinical phenotypes should guide research into disease mechanisms in asthma
Mosharaf et al. Computational identification of host genomic biomarkers highlighting their functions, pathways and regulators that influence SARS-CoV-2 infections and drug repurposing
Persson et al. Transcriptome analysis of controlled and therapy-resistant childhood asthma reveals distinct gene expression profiles
Puccetti et al. MicroRNA expression profiling in Behçet’s disease
JP7663969B2 (ja) ウイルス変異予測装置、ウイルス変異予測方法、およびプログラム
Shin et al. Hantaviruses induce cell type-and viral species-specific host microRNA expression signatures
GB2624986A (en) Methods and systems for therapy monitoring and trial design
Zahiruddin et al. Role of epigenetics and DNA-damage in asthma
JP2022130525A (ja) 気分障害検査用バイオマーカーとしてのｒｎａ編集
Chakraborty et al. A comprehensive analysis of the mutational landscape of the newly emerging Omicron (B. 1.1. 529) variant and comparison of mutations with VOCs and VOIs
Papakonstantinou et al. In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients
Alijani et al. Differential expression of miR-146 and miR-155 in active and latent tuberculosis infection
Zhu et al. Bioinformatic analyses of renal ischaemia-reperfusion injury models: identification of key genes involved in the development of kidney disease
Hu et al. Different microRNA alterations contribute to diverse outcomes following EV71 and CA16 infections: Insights from high-throughput sequencing in rhesus monkey peripheral blood mononuclear cells
Ding et al. Integration of transcriptomics and metabolomics identify biomarkers of aberrant lipid metabolism in ulcerative colitis
Baten et al. Coinfection of fungi with SARS-CoV-2 is a detrimental health risk for COVID-19 patients
Oyoshi et al. Filaggrin deficiency promotes the dissemination of cutaneously inoculated vaccinia virus
Tripp et al. Host gene expression and respiratory syncytial virus infection
JP2022049694A5 (enExample)
Navarro et al. 167 Herbal and dietary supplement induced hepatotoxicity in the US
Rezapour et al. Assessing concordance between RNA-Seq and NanoString technologies in Ebola-infected nonhuman primates using machine learning
Ponnoth et al. Involvement of A1 adenosine receptors in altered vascular responses and inflammation in an allergic mouse model of asthma
Muwonge et al. Unique circulating microRNA profiles in epidemic Kaposi's sarcoma
Wilk et al. Pro-inflammatory feedback loops define immune responses to pathogenic Lentivirus infection
Khamwut et al. Detection of respiratory syncytial virus based on RT-RPA and CRISPR-Cas12a